Skip to content

MAGIC-PAD Trial

Multicenter Aggressive wire recanalization in calcified atheroma and dilatation technique for GIant Calcified lesion in Peripheral Artery Disease trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1020220033
Enrollment
200
Registered
2022-11-29
Start date
2022-11-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis obliterans

Interventions

None listed

Sponsors

Koshida Ryoji
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)18 years of age or older 2)Peripheral artery disease with de novo Iliac/CFA/SFA/PopA eccentric calcified lesion>= 75% 3)Patients with an indication for EVT 4)Patients with accessible medical records throughout the observation term 5)Patients have provided written informed consent

Exclusion criteria

Exclusion criteria: 1)Inability to provide written informed consent 2) Life expectancy less than 12 months 3)Estimated high risk of non-availability for antiplatelet or anticoagulant medications 4)Patients with other reasons inappropriate for inclusion in the study

Design outcomes

Primary

MeasureTime frame
Primary patency at 12 & 24 months

Secondary

MeasureTime frame
1)Minimum lumen diameter 2)Eccentricity index of the target lesion 3)Change in Ankle-Brachial Index before and after EVT 4)Technical success rate of ARCADIA technique 5)Ankle-Brachial Index at 12 and 24 months 6)Rutherford class at 12 and 24 months 7)Procedural complications 8)Procedural time, fluoroscopy time, radiation dose, Contrast volume 9)Minimum lumen diameter by contrast CT at 12 and 24 months (Iliac only)

Contacts

Public ContactHirokazu Konishi

Tokyo Metropolitan Tobu Chiiki Hospital, Tokyo Metoropolitan Hospital Organization

h-kony0408@ozzio.jp+81-3-5682-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026